Yes, Ozempic is FDA-approved specifically for type 2 diabetes. It was first approved in 2017 as a once-weekly injection to improve blood sugar control in adults with type 2 diabetes, used alongside diet and exercise. It also carries a second approval: reducing the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who already have heart disease.
How Ozempic Lowers Blood Sugar
Ozempic contains semaglutide, which mimics a natural hormone called GLP-1 that your body releases after eating. This hormone does three things that matter for blood sugar control. First, it signals your pancreas to release more insulin, but only when your blood sugar is actually elevated. This glucose-dependent action means it carries a lower risk of causing dangerously low blood sugar compared to some older diabetes medications. Second, it suppresses glucagon, a hormone that tells your liver to release stored sugar into the bloodstream. With less glucagon activity, your fasting blood sugar drops. Third, it slows how quickly food leaves your stomach, which prevents the sharp blood sugar spikes that typically follow meals.
That slower digestion also prolongs the feeling of fullness after eating, which is why many people on Ozempic lose weight. The weight loss is a secondary benefit for people with type 2 diabetes, not the primary reason it’s prescribed under this brand name.
How Much It Reduces Blood Sugar
In clinical trials, a 1 mg weekly dose of Ozempic lowered HbA1c (a measure of average blood sugar over roughly three months) by 1.5% to 1.8% after 30 to 56 weeks. A separate meta-analysis of the same trial program found a 1.37% reduction. To put that in perspective, most diabetes guidelines consider a drop of 1% or more clinically meaningful. For many people, that reduction is enough to bring HbA1c from a poorly controlled range into a target range below 7%.
Cardiovascular and Kidney Benefits
Beyond blood sugar, Ozempic has shown real protective effects for the heart. Across two large clinical trials, semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 24% compared to placebo in people with type 2 diabetes. This is why the FDA granted it a specific cardiovascular indication, not just a diabetes one.
Ozempic has also been studied for its effects on kidney health in people with type 2 diabetes and chronic kidney disease. The FLOW trial examined whether semaglutide could slow the progression of kidney disease, looking at outcomes like significant loss of kidney function, the need for dialysis or transplant, and kidney-related death. Based on these results, Ozempic now carries an indication for improving kidney and cardiovascular health in adults with type 2 diabetes and chronic kidney disease.
How It’s Taken
Ozempic is a once-weekly injection given under the skin using a prefilled pen. You pick one day of the week and inject at the same time each week, with or without food. The three recommended injection sites are the front or outer thigh, the back or side of the upper arm, and the abdomen (at least two inches from the belly button). Absorption is the same regardless of which site you choose, so the medication works equally well in all three locations. Rotating between sites with each dose helps prevent skin irritation, bruising, and the buildup of lumpy fat tissue that can develop from repeated injections in the same spot.
The starting dose of 0.25 mg is not actually a treatment dose. It exists purely to let your body adjust and minimize side effects. After four weeks at 0.25 mg, the dose increases to 0.5 mg. From there, your prescriber can increase to 1 mg and eventually to a maximum of 2 mg, depending on how well your blood sugar responds and how you tolerate the medication. Each step up typically lasts at least four weeks.
Common Side Effects
The most frequent side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation, each occurring in at least 5% of patients in clinical trials. These tend to be worst during dose increases and often improve over time as your body adjusts. At the 1 mg dose, about 30.8% of patients experienced some form of GI side effect, rising to 34% at the 2 mg dose. Severe GI reactions were uncommon, affecting less than 1% of patients. About 3% to 4% of people in trials stopped taking Ozempic because of stomach-related side effects, compared to 0.4% on placebo.
The FDA label carries a boxed warning about thyroid tumors. In rodent studies, semaglutide caused a type of thyroid cancer called medullary thyroid carcinoma. Whether this risk applies to humans is unknown. Ozempic should not be used by anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
How Ozempic Differs From Wegovy
Both Ozempic and Wegovy contain the same active ingredient, semaglutide, but they are approved for different purposes and prescribed at different doses. Ozempic is approved for managing type 2 diabetes (maximum dose 2 mg weekly), while Wegovy is approved for weight management in adults and children 12 and older (maximum dose 2.4 mg weekly). Wegovy also has approvals for a type of liver disease called MASH and for cardiovascular risk reduction in adults with obesity or overweight and heart disease. If your primary diagnosis is type 2 diabetes, Ozempic is the version your prescriber will typically reach for, and insurance coverage generally follows the approved indication.